Overall statistics
| Procedures . | IGHV1-69 (U/M) . | IGHV2 or IGHV3 (U/M) . | All (U/M) . |
|---|---|---|---|
| Total no. of samples stimulated with EBV | 37 (35/2) | 29 (12/17) | 66 (47/19) |
| No. of samples with at least 50% of wells with IgM | 25 (23/2) | 16 (8/8) | 41 (31/10) |
| % samples producing total IgM* | 67.6% | 55.2% | 62.1% |
| No. of EBV-B-cell lines sequenced | 11 (10/1) | 10 (5/5) | 21 (15/6) |
| No. of EBV-B-cell lines with matched Ig sequences† | 9 (9/0) | 4 (3/1) | 13 (12/1) |
| % EBV-B-cell lines from B-CLL* | 81.8% | 40.0% | 61.9% |
| No. of EBV-B-cell lines electrofused | 8 (8/0) | 2 (1/1) | 10 (9/1) |
| No. of hetero-hybridoma cloned and sequenced | 6 (6/0) | 1 (0/1) | 7 (6/1) |
| No. of matched hetero-hybridoma clones | 5 (5/0) | 1 (0/1) | 6 (5/1) |
| Procedures . | IGHV1-69 (U/M) . | IGHV2 or IGHV3 (U/M) . | All (U/M) . |
|---|---|---|---|
| Total no. of samples stimulated with EBV | 37 (35/2) | 29 (12/17) | 66 (47/19) |
| No. of samples with at least 50% of wells with IgM | 25 (23/2) | 16 (8/8) | 41 (31/10) |
| % samples producing total IgM* | 67.6% | 55.2% | 62.1% |
| No. of EBV-B-cell lines sequenced | 11 (10/1) | 10 (5/5) | 21 (15/6) |
| No. of EBV-B-cell lines with matched Ig sequences† | 9 (9/0) | 4 (3/1) | 13 (12/1) |
| % EBV-B-cell lines from B-CLL* | 81.8% | 40.0% | 61.9% |
| No. of EBV-B-cell lines electrofused | 8 (8/0) | 2 (1/1) | 10 (9/1) |
| No. of hetero-hybridoma cloned and sequenced | 6 (6/0) | 1 (0/1) | 7 (6/1) |
| No. of matched hetero-hybridoma clones | 5 (5/0) | 1 (0/1) | 6 (5/1) |
Numbers in parentheses represent unmutated (U) type/mutated (M) type, respectively.
The overall efficiency of B-CLL outgrowth was based on the following equation: % samples producing IgM (62.1%) × % B-cell lines with the matched Ig sequences (61.9%) = 38.4%.
The EBV-transformed B (EBV-B) cells with matched Ig sequences had IGHV sequences that matched those of the previously identified B-CLL IgM sequences from the same patient samples.30